GleamWall
中文EN

GANX Gain Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1819411 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.3%
TTM EPS YoY31.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-223.9%
ROA-148.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.3%
Debt / equity0.03x
Current ratio5.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.42M$2.14M$2.76M$2.35M$2.85M$2.76M$2.26M$1.22M
SG&A expense$1.78M$2.54M$2.59M$2.12M$1.94M$2.33M$2.11M$2.11M
Operating income-$3.20M-$4.68M-$5.35M-$4.47M-$4.79M-$5.09M-$4.37M-$3.33M
Pretax income-$3.09M-$4.57M-$5.43M-$4.47M-$4.74M-$5.67M-$4.43M-$3.26M
Income tax$72,489$104,070$183,066$70,116$549,288$141,205$100,509$504,738
Net income-$3.16M-$4.68M-$5.61M-$4.54M-$5.28M-$5.81M-$4.53M-$3.77M
EBITDA-$3.20M-$4.67M-$5.33M-$4.44M-$4.78M-$5.08M-$4.35M-$3.31M
EPS (basic)-0.07-0.11-0.13—-0.15-0.19-0.16—
EPS (diluted)-0.07-0.11-0.13—-0.15-0.19-0.16—
Weighted avg. shares (diluted)43.77M42.88M42.23M—35.00M30.34M28.69M—
Balance sheet
Cash & equivalents$11.70M$13.08M$16.54M$20.84M$8.84M$6.73M$9.10M$10.42M
Current assets$12.70M$14.97M$18.22M$22.24M$10.52M$9.31M$11.15M$11.60M
PP&E, net$40,324$47,026$54,435$74,916$85,572$96,190$97,509$103,619
Intangibles$65,741——$102,837————
Total assets$13.23M$15.42M$18.74M$22.82M$10.97M$9.83M$11.62M$12.12M
Current liabilities$2.37M$3.43M$3.89M$3.35M$4.17M$5.20M$5.03M$3.91M
Short-term debt$119,656$123,628$100,281$100,869$125,545$126,108$113,121$110,177
Long-term debt$189,056$220,058$273,265$300,084$298,797$325,359$314,476$328,327
Total debt$308,712$343,686$373,546$400,953$424,342$451,467$427,597$438,504
Total liabilities$3.08M$4.13M$4.73M$4.25M$5.06M$6.14M$5.84M$4.78M
Shareholders' equity$10.15M$11.29M$14.01M$18.56M$5.91M$3.70M$5.78M$7.34M
Net debt-$11.39M-$12.74M-$16.17M-$20.44M-$8.42M-$6.28M-$8.68M-$9.98M
Shares outstanding44.32M43.34M42.49M42.07M35.98M30.77M28.75M27.13M
Cash flow statement
Operating cash flow-$3.05M-$4.68M-$4.73M-$4.62M-$4.93M-$5.10M-$3.82M-$3.45M
Capital expenditure———————$945
Free cash flow———————-$3.46M
Investing cash flow———————-$43,447
Financing cash flow$1.75M$1.37M$404,321$16.55M$7.03M$2.47M$2.40M$2.31M
Depreciation & amortization$7,000$15,000$21,303$28,241$10,000$10,000$20,660$21,307
Stock-based compensation$375,649$566,049$403,509$401,667$460,005$522,019$419,504$359,329

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.